Chlamydia Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Chlamydia Infections - Pipeline Review, H1 2016', provides an overview of the Chlamydia Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chlamydia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections - The report reviews pipeline therapeutics for Chlamydia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Chlamydia Infections therapeutics and enlists all their major and minor projects - The report assesses Chlamydia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Chlamydia Infections Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Chlamydia Infections Overview 7 Therapeutics Development 8 Pipeline Products for Chlamydia Infections - Overview 8 Pipeline Products for Chlamydia Infections - Comparative Analysis 9 Chlamydia Infections - Therapeutics under Development by Companies 10 Chlamydia Infections - Therapeutics under Investigation by Universities/Institutes 11 Chlamydia Infections - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Chlamydia Infections - Products under Development by Companies 14 Chlamydia Infections - Products under Investigation by Universities/Institutes 15 Chlamydia Infections - Companies Involved in Therapeutics Development 16 Abera Bioscience AB 16 Adamis Pharmaceuticals Corporation 17 CEL-SCI Corporation 18 Genocea Biosciences, Inc. 19 Merck & Co., Inc. 20 NanoBio Corporation 21 Prokarium Limited 22 QureTech Bio AB 23 Selecta Biosciences, Inc. 24 SIGA Technologies, Inc. 25 Chlamydia Infections - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 Ab-03 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 acALY-18 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 C-31G - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 CEL-1000 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Chlamydia trachomatis vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Chlamydia trachomatis vaccine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Chlamydia vaccine - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 chlamydia vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Chlamydia vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Chlamydia vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Chlamydia vaccine - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Chlamydia vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 GEN-001 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecules for Chlamydophila Infections - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 solithromycin - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ST-669 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Chlamydia Infections - Recent Pipeline Updates 58 Chlamydia Infections - Dormant Projects 69 Chlamydia Infections - Product Development Milestones 70 Featured News & Press Releases 70 Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice 70 Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology 70 Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia 71 Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection 72 Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria 72 Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center's Sexually Transmitted Infections Cooperative Research Center 73 Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified 74 Appendix 75 Methodology 75 Coverage 75 Secondary Research 75 Primary Research 75 Expert Panel Validation 75 Contact Us 75 Disclaimer 76
List of Tables
Number of Products under Development for Chlamydia Infections, H1 2016 8 Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Chlamydia Infections - Pipeline by Abera Bioscience AB, H1 2016 16 Chlamydia Infections - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016 17 Chlamydia Infections - Pipeline by CEL-SCI Corporation, H1 2016 18 Chlamydia Infections - Pipeline by Genocea Biosciences, Inc., H1 2016 19 Chlamydia Infections - Pipeline by Merck & Co., Inc., H1 2016 20 Chlamydia Infections - Pipeline by NanoBio Corporation, H1 2016 21 Chlamydia Infections - Pipeline by Prokarium Limited, H1 2016 22 Chlamydia Infections - Pipeline by QureTech Bio AB, H1 2016 23 Chlamydia Infections - Pipeline by Selecta Biosciences, Inc., H1 2016 24 Chlamydia Infections - Pipeline by SIGA Technologies, Inc., H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Chlamydia Infections Therapeutics - Recent Pipeline Updates, H1 2016 58 Chlamydia Infections - Dormant Projects, H1 2016 69
List of Figures
Number of Products under Development for Chlamydia Infections, H1 2016 8 Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Targets, H1 2016 27 Number of Products by Stage and Targets, H1 2016 27 Number of Products by Mechanism of Actions, H1 2016 29 Number of Products by Stage and Mechanism of Actions, H1 2016 29 Number of Products by Routes of Administration, H1 2016 31 Number of Products by Stage and Routes of Administration, H1 2016 31 Number of Products by Molecule Types, H1 2016 33 Number of Products by Stage and Molecule Types, H1 2016 33
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealanRead More...
Global heat transfer fluids market size is likely to be valued at USD 3.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing demand for for heat recovery management in industries such as metal processing, pharmaceuticaRead More...
Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growtRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.